In the German pharmaceutical industry, there were 3 private equity deals announced in Q2 2023, worth a total value of $271.4m, according to GlobalData’s Deals Database. The $271.4m investment by montana capital partners in Sanecum Group was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes, the M&A activity and most notable deals are included in GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.
In value terms, private equity deal activity in Germany decreased by 38% in Q2 2023 compared with the previous quarter’s total of $435m. Related deal volume increased by 50% in Q2 2023 versus the previous quarter and was 200% higher than in Q2 2022.
The top-ranked financial advisors supporting these private equity deals in Germany in Q2 2023 were Deloitte Touche Tohmatsu; Flick Gocke Schaumburg; Houlihan Lokey with 1, 1, 1 deals respectively.
The top-ranked legal advisorss supporting these private equity deals in Germany Q2 2023 were Baker & McKenzie; Gowling WLG International; Hengeler Mueller Partnerschaft von Rechtsanwalten mbB with 2, 1, 1 deals respectively.
For further understanding of GlobalData's Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.